The culmination of these data highlights COX-2 as a potent oncogene that enhances the targeted resistance of NSCLC cells through its interaction with EGFR, and subsequent activation of the EGFR/PI3K/AKT axis. Here, PTGS2 is linked to non-small cell lung carcinoma.